Aclaris holds R&D Day presenting I&I pipeline; no specific data disclosed in filing

Aclaris Therapeutics, Inc.

R&D Day held Oct 14, 2025, focusing on immunology and inflammation (I&I) therapeutic franchises.
Presentation furnished as Exhibit 99.1; available on Investor Relations section of company website.
No financial results, clinical data, or guidance changes were included in the 8-K or exhibit snippet.
Company continues to develop pipeline for gaps in I&I diseases; no material updates provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.